Gossiel, F.
Ugur, A.
Peel, N. F. A.
Walsh, J. S.
Eastell, R.
Article History
Received: 28 July 2021
Accepted: 17 January 2022
First Online: 31 January 2022
Declarations
:
: R Eastell receives consultancy funding from IDS, Sandoz, Nittobo, Samsung, Haoma Medica, CL Bio, Biocon, Amgen, Hindustan Unilever, Pharmacosmos, Takeda and Viking and grant funding from Nittobo, Roche, Pharmacosmos and Alexion. J Walsh has received speaker’s honoraria from Lilly and the donation of drug and placebo from Prostrakan. N Peel has received speaker’s honoraria and funding to attend educational events from Warner-Chilcott, Lilly, Amgen, GSK and Prostrakan and consultancy fees from Internis Pharma and Lilly. F Gossiel and A Ugar declare that they have no conflict of interest.